The Ministry of Health is considering the following drugs for PharmaCare coverage:

Generic name: maralixibat

               Brand name: Livmarli®

Drug used for: Progressive familial intrahepatic cholestasis (PFIC) in patients three months of age and older

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

Generic name: avacincaptad pegol

               Brand name: Izervay™

Drug used for: Non-foveal geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

Generic name: lecanemab

               Brand name: Leqembi®

Drug used for: Adult patients with Alzheimer’s disease (mild cognitive impairment or mild dementia stage of disease, apolipoprotein E ε4 noncarriers or heterozygotes, with confirmed amyloid pathology)

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

               Generic name: seladelpar

               Brand name: Lyvdelzi®

               Drug used for: Primary biliary cholangitis (PBC) in adults

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

               Generic name: palopegteriparatide

               Brand name: TBC (to be confirmed)

Drug used for: Chronic hypoparathyroidism (hypoPT) in adults not adequately controlled with conventional therapy

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

               Generic name: epinephrine nasal spray

               Brand name: neffy^TM

Drug used for: Emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

               Generic name: vamorolone

               Brand name: Agamree®

               Drug used for: Duchenne muscular dystrophy (DMD) in patients 4 years of age and older

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

               Generic name: nipocalimab

               Brand name: Imaavy®

Drug used for: Generalized myasthenia gravis (gMG) in adult and adolescent patients aged 12 years and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive 

Input accepted: From Wednesday, December 31, 2025, to Tuesday, January 27, 2026,

AT 11:59 PM

To provide input, please visit our website at http://www.gov.bc.ca/bcyourvoice.

IMPORTANT: The Ministry of Health must receive input for the drugs listed above no later than 11:59 PM on Tuesday, January 27, 2026

Thank you,

Health System Policy and Oversight Division - B.C. Ministry of Health